MAL-di-EG-Val-Cit-PAB-MMAF is a drug-linker conjugate containing the ADC linker MAL-di-EG-Val-Cit-PAB and the tubulin polymerization blocker MMAF.
Structure of
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-01432 | Cys-MC-MMAF | 1160590-05-5 | |
BADC-00592 | MC-Alkyl-Hydrazine Modified MMAF | 1404071-64-2 | |
BADC-01455 | Modified MMAF-C5-COOH | 1404071-65-3 | |
BADC-00594 | PEG4-aminooxy-MMAF | 1415246-35-3 | |
BADC-00320 | MMAF Hydrochloride | 1415246-68-2 | |
BADC-00617 | MMAF sodium | 1799706-65-2 | |
BADC-01460 | DBM-MMAF | 1810001-93-4 | |
BADC-00863 | DBCO-PEG4-Val-Cit-PAB-MMAF | 2244602-23-9 | |
BADC-00751 | DBCO-PEG4-MMAF | 2360411-65-8 | |
BADC-00318 | MMAF | 745017-94-1 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.